SITC Poster #59: Since the emergence of the COVID-19 pandemic, numerous nucleic-acid therapeutics have been approved for clinical use. Distinguished from conventional protein-targeted therapy, nucleic acid therapeutics offer the potential for sustained effects via gene modification or inhibition. In this study, we conducted a comprehensive evaluation of the activity and anti-tumor effects of PKN3-targeted siRNA …Read More >

SITC Poster #1162: Enhertu is currently approved for the treatment of patients with HER2-positive breast cancer, gastric cancer, or HER2-mutant non-small cell lung cancer. However, despite Enhertu’s clinical benefits, most patients inevitably experience disease progression and mortality. Understanding drug resistance mechanisms can aid in developing new treatment strategies for drug-resistant clinical patients. In this study, …Read More >

RecQ helicases (BLM, WRN, RECQL, RECQL4, and RECQL5) are an important family of surveillance proteins that play critical roles in genome maintenance and stability. Inherited mutations in these helicases are linked to distinct human disease syndromes, as well as cancer. To support the discovery of potent and selective RecQ helicase inhibitors, WuXi AppTec offers a …Read More >

Cyclin-dependent kinases (CDKs) and their cyclin regulatory subunits form complexes that are essential for driving abnormal growth processes in cancer cells, making these molecules important targets for cancer treatment. To support the discovery of novel CDK inhibitors, WuXi AppTec offers a comprehensive platform of biophysical and biochemical assays to accelerate hit finding and lead optimization …Read More >

Tumors and anti-tumor therapies may cause diverse systemic complications. Treatment of these complications is essential in optimizing quality of life and improving the clinical value of cancer therapies. WuXi AppTec offers well-established in vivo tumor complication-related models in a translationally relevant platform to support drug discovery teams. Our panel includes cancer models representing cachexia, diarrhea, …Read More >

Introduction: Over the last few years, the clinical success of immune checkpoint inhibitors has increasingly drawn attention to cancer therapies that target the tumor microenvironment (TME). TME consists of various cell types that are embedded in the extracellular matrix (ECM), including immune cells, endothelial cells, and cancer associated fibroblasts, all of which play critical roles …Read More >

WuXi AppTec provides a comprehensive platform of advanced biophysical assays and structural biology services to accelerate lead optimization efforts focused on GPCRs and membrane proteins. Our capabilities include high-quality protein production across all major target classes and nanodisc reconstitution of membrane proteins for screening. We also offer established protocols for cryo-EM structure determination and assessment …Read More >

SITC Poster #466: Mutant KRAS is linked to PD-L1 expression, and oncogenic RAS signaling promotes an immunosuppressive tumor microenvironment by upregulating PD-L1 expression. Consequently, combining KRAS G12C inhibitors with immune checkpoint blockers shows promising benefits. To better understand the mechanisms underlying the combined inhibition of KRAS G12C inhibitor AMG 510, and anti-PD-1 antibody nivolumab, LU-01-0361 …Read More >

Introduction: Cancer is a major public health concern, and this disease is a leading cause of death worldwide. There are over 200 different types of cancer, and such complexity has slowed the rate of progress being made by researchers. Encouragingly, the emergence of immunotherapies, especially tumor vaccines, brings hope to cancer patients. Personalized tumor vaccines …Read More >